3D PRINTED TITANIUM PLIF CAGE

3D PRINTED INTERBODIES

Hexanium® PLIF



SURGICAL TECHNIQUE

SPINEVISION

INNOVATION THAT MATTERS

SpineVision® Hexanium PLIF: Posterior Lumbar Interbody Fusion

Intended Purpose

The Hexanium PLIF (Posterior Lumbar Interbody Fusion) is intended to give a primary stability of the anterior column, via a posterior approach, with or without restoring disc height until fusion occurs.

Hexanium PLIF intervertebral body fusion device must be combined with an appropriate posterior lumbar fixation device, e.g. the SpineVision®, PLUS®, ULIS™ or LUMIS™.

Description

The Hexanium PLIF (Posterior Lumbar Interbody Fusion) system is an intervertebral body fusion device of the lumbar spine (L2-S1).

The Hexanium PLIF system consists of cages of various widths, heights, and angulations, which can be inserted between two vertebral bodies to give support and correction during lumbar interbody fusion surgeries. The hollow geometry of the implants allows them to be packed with bone graft.

For the Hexanium PLIF system, two cages must be used per segment for fusion in order to stabilize the segment concerned. The Hexanium PLIF is indicated for use with autogenous bone.

All cages are manufactured from implant grade Titanium (Ti6Al4V compliant with ASTM F3001).

Indications

The Hexanium PLIF (Posterior Lumbar Interbody Fusion) system is an intervertebral body fusion device indicated for use with autogenous bone graft in skeletally mature patients with Degenerative Disc (DDD) at one or two continuous levels from L2-S1. DDD is defined as discogenic back pain with degeneration of the disc confirmed by patient history and radiographic studies. These DDD patients may also have up to Grade I spondylolisthesis or retrolisthesis at the involved level(s). Patients should have received at least 6 months of non-operative treatment prior to treatment with the Hexanium PLIF system. This device has to be filled with autogenous bone graft material. This device is implanted via the posterior approach. The Hexanium PLIF system must be used in combination with supplemental internal spinal fixation which has been cleared by the FDA for use in the lumbar spine.

Contraindications

TThis device is not intended for thoracic or cervical spine use. Contraindications include:

- infection local to the operative site, signs of local inflammation, leukocytosis;
- fever;
- morbid obesity (BMI ≥ 40 kg/m²);
- pregnant woman should not undergo a surgery;
- pediatric cases, or patient still having general skeletal growth;
- spondylolisthesis unable to be reduced to Grade I;
- suspected or documented allergy or intolerance to composite materials;
- any case where the implant components selected for use would be too large or too small to achieve a successful result.
- any patient having inadequate tissue coverage over the operative site or inadequate bone stock or quality.
- any patient in which implant utilization would interfere with anatomical structures or expected physiological performance.
- previous fusion at the level to be treated.
- any case not needing a bone graft or fusion;
- any abnormality present which affects the normal process of bone remodeling including, but not limited to, severe osteoporosis involving the spine, bone absorption, osteopenia, primary or metastatic tumors involving the spine, active infection at the site or certain metabolic disorders affecting osteogenesis;
- any other condition which would preclude the potential benefit of spinal implant surgery, such as the presence of tumors or congenital abnormalities, fracture local to the operating site, elevation of segmentation rate unexplained by other diseases, elevation of white blood count (WBC), or a marked left shift in the WBC differential count;
- patient's inability to follow practitioner recommendations;
- any patient unwilling to cooperate with postoperative instructions.

The contraindications of these devices are similar to those of other spinal interbody systems. This spinal instrumentation is not designed, or intended, or sold for uses other than those indicated.

These contraindications must be taken into account by the physician when making his decision.

Potential Adverse Events

In addition to the risks associated with spinal surgery without instrumentation, the following potential adverse events can occur:

- delayed union;
- non-union (or pseudoarthrosis);
- bone fracture or stress shielding at, above, or below the level of surgery, microfracture, resorption, or damage of any spinal bone (including the sacrum, pedicles, and/or vertebral body) and/or bone graft or bone graft harvest site;
- retropulsed graft;
- loosening, or migration of implant, that may result in paralysis, neurological disorders or blood vessel erosion due to the proximity of the device;
- loss of neurological function, appearance of radiculopathy, dural tears, and/or development of pain, neurovascular compromise including paralysis, temporary or permanent retrograde ejaculation in males, or other types of serious injury, cerebral spinal fluid leakage;
- infection;
- hemorrhage of blood vessels and/or hematomas;
- discitis, arachnoiditis, and/or other types of inflammation;
- subsidence of implant into adjacent vertebral bodies resulting in loss of height and possible impingement of neural structures;
- loss of proper spinal curvature, correction, height, and/or reduction;
- pain, discomfort, or other abnormal sensations due to the presence of the device;
- herniated nucleus pulposus, disc disruption or degeneration above, or below the level of surgery;
- loss of or increase in spinal mobility or function;
- pressure on the surrounding tissues or organs;
- foreign body reaction due to the presence of implants, such as a mass, auto-immune disease, and/or impaired healing;
- cessation of any potential growth of the operated portion of the spine,
- deep venous thrombosis, thrombophlebitis;
- development of respiratory problems, e.g. pulmonary embolism, atelectasis, bronchitis, pneumonia, etc.;
- bone graft donor site complication;
- urinary retention or loss of bladder control or other types of urological system compromise;
- scar formation possibly causing neurological compromise or compression around nerves and/or pain;
- change in mental status;
- incapacity to resume the activities of normal everyday life;
- death.

Note: Some potential adverse events may require an additional surgical revision procedure.

Intended users

Trained orthopedic surgeon or neurosurgeon on the Hexanium PLIF use, and familiar with its recommendations as well as with the operating techniques.

Patient target groups

Skeletally mature patients, regardless of gender.

Storage and packaging

Packages for each of the components should be intact upon receipt. Care should be taken not to damage the implants when opening the packaging. For implant supplied in a sterile form, carefully check that the seal on the cardboard box is intact before you open the box. Damaged packages or products must not be used. If in doubt, please send them back to SpineVision® or to the distributor.

Inspection, cleaning and sterilization

Hexanium PLIF implants are delivered sterile by exposure to a minimum dose of 25kGy of gamma radiation. They must be never resterilized.

Hexanium PLIF implants must only be used with the Hexanium PLIF ancillary equipment. Hexanium PLIF ancillary equipment are supplied not sterile. They must be sterilized before use.

All packaging and labeling materials must be removed prior to sterilization. Decontamination and cleaning must be performed before sterilization. Further information regarding cleaning and sterilization of SpineVision products are available in the instruction I-LG09 "Instructions for cleaning, sterilization, inspection and maintenance of SpineVision medical devices".

Cleaning and decontamination of the non-sterile instruments at the Healthcare facility:

It is recommended to use a neutral pH, enzymatic or alkaline (pH < 11) cleaning agent solution and deionized or distilled warm (room temperature) water of soaking, cleaning and rinsing.

Dismantle the necessary instruments. Articulated instruments must be opened.

Inspect each device and repeat the washing in the presence of any residual debris, paying close attention to threads, cannulas, hinges and hard to reach areas.

Note: Certain cleaning solutions, such as those containing bleach or formaldehyde, may damage certain components and must not be used.

Verification

The devices must always be verified before use: any devices presenting signs of weakness or surface scratches must not be used. (Return to the manufacturer or distributor any implants showing deterioration).

Sterilization

Prior to use, Hexanium PLIF instruments should be double wrapped using FDA-cleared sterilization wraps and steam sterilized according to the following parameters:

Method	Steam
Cycle	Prevacuum
Temperature	132°C (270°F)
Minimum exposure time	4 minutes
Minimum drying time	30 minutes

Validations were performed with dynamic-air-removal steam sterilization process.

Warnings and precautions

PREOPERATIVE

- The use of the Hexanium PLIF has to be done using dedicated adequate instrumentation by a trained orthopedic surgeon or neurosurgeon familiar with these recommendations as well as with the operating techniques relating to these implants.
- The surgeon must be aware of not only the medical and surgical aspects of the implant, but also of the material limitations of titanium implants. The patient must be instructed in the limitations of the implant, especially with regard to the weight bearing and other body stresses on the device before a solid fusion occurs. The patient must be instructed that non-compliance with postoperative instructions could lead to failure of the device. The patient must be instructed that device failure could lead to the need for additional surgery to remove failed components.
- Patients should have received at least 6 weeks of non-operative treatment prior to treatment with Hexanium PLIF system.
- Only patients that meet the criteria described in the indications should be selected and patients corresponding to the aforementioned contra-indications should not be selected. The following factors may be of importance when selecting patients for internal stabilization devices:
  - Foreign body sensitivity;
  - certain degenerative diseases;
  - senility, mental illness, alcoholism, or drug abuse;
  - obesity;
  - patient's occupation or activity level;
  - smoking.
- Additional sterile components should be available in case of any unexpected need.

INTRAOPERATIVE (please see surgical technique GPL2-ST, latest applicable version at SpineVision)

- Correct handling of the implants is extremely important. The implants must be transported in a way not to incur any damage. The implants must not be scratched and must not collide during handling.
- Care must be taken when picking up the Hexanium PLIF implant, filling it with bone graft and inserting it between the vertebral bodies. Alterations may produce defects in surface finish and may become the focal point for eventual breakage of the implant or for decreased efficacy in withstanding post-operative migration (e.g. when teeth of implant are damaged).
- Correct selection of the implant size is extremely important. The chance of adequate stabilization is increased by the selection of the proper size of the implant regarding the anatomy and conditions of the patient. Proper selection of the implant can minimize, but not eliminate risks.
- The Hexanium PLIF components have been designed for use with this system. Do not use the Hexanium PLIF with any components not specifically recommended, or with any components from another manufacturer.
- The Hexanium PLIF cannot be inserted via an anterior approach.
- The Hexanium PLIF cannot be used in cervical and thoracic spine.
- The implant should be placed on the peripheral cortical bone of the endplates to minimize the risk of post-operative subsidence.
- Surgical implants must never be reused. An explanted implant should never be reimplanted. Even though a device appears undamaged, it may have small defects and internal stress patterns that may lead to early breakage.

POSTOPERATIVE

- Careful patient monitoring for the first two to four months following the operation is very important while the fusion mass matures and becomes able to share load with the implant. Adequately instruct the patient in the appropriate postoperative care. The patient must be instructed to reduce stress on the implants in order to avoid clinical problems that may accompany failed fixation. The patient's ability and willingness to follow instructions are one of the most important aspects of successful bone healing. The patient must be instructed in the limitations of the implant, and that physical activity and full weight bearing may cause premature failure of internal stabilization devices by migrating, loosening or fracture. The patient must be instructed that an implant does not have the strength of normal healthy bone, and that device failure may occur if excessive loading is placed on the implant. An active, debilitated, or demented patient who is unable to use orthotic weight bearing devices may be particularly at risk.
- No internal stabilization device can withstand activity levels equal to those withstood by normal healthy segment. No implant can be expected to withstand unsupported weight-bearing stress indefinitely.
- Implants may fail when subjected to the increased loading associated with delayed union or non-union. Internal stabilization devices are intended as load-sharing devices until normal healing occurs. If normal healing does not occur or is delayed, the device may break due to fatigue. Patients should be informed of the risks of implant failure.

Magnetic Resonance (MR) Safety: The Hexanium PLIF has not been evaluated for safety and compatibility in the MR environment. The Hexanium PLIF has not been tested for heating or migration in the MR environment.

Disposal

Disposal of all infectious wastes (implants) must be in accordance with applicable national and local regulations and the medical waste protocol of the medical center, and not endanger the security or the health of patient, user, or another person until its complete disposal (including cleaning, decontamination and waste).

Product complaints

Any health care professional (e.g., customer or user of this system of products), who has any complaints or who has experienced any dissatisfaction in the product quality, identification, durability, reliability, safety, effectiveness and/or performance, should notify SpineVision® or the distributor. Further, if any of the implanted Hexanium PLIF components does not meet any of its performance specifications or otherwise does not perform as intended, or is suspected of doing so, SpineVision® should be notified immediately.

If any SpineVision® product may have caused or contributed to the death or serious injury of a patient, SpineVision® should be notified as soon as possible by telephone, or written correspondence. When filing a complaint, please provide the component(s) name and number, lot number(s), your name and address, the nature of the complaint and notification of whether a written report is requested from SpineVision®.

FOR ALL INFORMATION OR COMPLAINTS, CONTACT:

In Europe
SpineVision
10 Rue de la Renaissance
92160 Antony France Tél.:
+33 (0) 1 5333 2525 Fax:
+33 (0) 1 5333 2539

In USA
SpineVision Inc.
155 Federal Street
6th Floor – Suite 604
Boston, MA 02110 - USAPhone: +1 888 770 4118
Fax: +1 888 770 4119

Email: corp.quality@spinevision.com

⚠	See package insert for labeling limitation
	Do not use if package is damaged
	Expiration date
	Do not re-use
	Keep dry
	Keep away from sunlight
STERILE R	Sterilized using Irradiation
Rx only	Federal law (US) restricts this device to sale by or on the order of a physician
i	Consult instructions for use
LOT	Batch code
	Manufacturer
REF	Catalog number
	Do not re-sterilize
MD	Medical Device

IMPORTANT INFORMATION CONCERNING HEXANIUM PLIF INSTRUMENTATION

SURGICAL STEPS

I . . Patient preparation. 02
II . . Exposure. 02
III . . Endplate preparation. 03
IV . . Implant's size estimation. 06
V . . Cage bone graft filling. 08
VI . . Cage insertion. 09
VII . . Cage repositioning. 10
VIII . . Cage removal. 11

REFERENCES

1 . . Instruments. 12
2 . . Implants. 16

PATIENT PREPARATION

The patient is placed on the OR (Operating Room) table using the standard position indicated for Posterior Lumbar Interbody Fusion (PLIF).

X-ray shall be used during the entire procedure: to confirm identification of the affected disc, to confirm good positioning of the trial device and the final position of the Hexanium PLIF cage.



EXPOSURE

Dura Retractor 06 mm
PL1-A001-06



Dura Retractor 08 mm
PL1-A001-08

Mark the affected segment after c-arm control. Perform the incision over the level on which the cage must be inserted.

Expose the facets and the posterior parts of facet joints (on each side).

Normally (part of) the inferior facet of the upper vertebra and (part of) the superior facet of the lower vertebra are removed on the affected side with an osteotome, burr or kerrison.

Decompress the central spinal canal and the neural foramen if necessary.

Create a window in the posterior portion of the annulus to access the intervertebral space.



The dura and nerve root are protected using the **dura retractor 06 mm** *PL1-A001-06* and/or the **dura retractor 08 mm** *PL1-A001-08*.



ENDPLATE PREPARATION



Spreader
TL3-A010-XX



Reamer
TL3-A011-XX



Snap-On Cannulated Silicon T-Handle
SD-ATSH1169214C5

To connect a **spreader** *TL3-A010-xx* or a **reamer** *TL3-A011-xx* to the **snap-on cannulated silicon T-Handle** *SD-ATSH1169214C5*, pull the ring of the silicon T-handle towards the silicon part.

While maintaining this position, insert the square tip of the **spreader** or **reamer** into the handle and release the ring of the handle to secure the connection between the two instruments.

Always double check the connection of the two pieces.





To ensure good primary stability of the implant after implantation, it is mandatory to adequately distract the intervertebral disc space.

To perform this distraction, you can use the **spreaders** *TL3-A010-xx* 7 to 16.

It is recommended to start with the smallest **spreader** *TL3-A0106xx* to avoid excessive distraction.

Apply the **spreader** parallel to the intervertebral space and carefully do a quarter turn clockwise to open up the disc space.

During the distraction, insert alternately from side to another the **spreaders**, increasing their size with each change, until you reach the required distraction.

Use rongeurs and forceps to remove disc material thanks to the window created with the spreader. Leave only the anterior and lateral part of the annulus.





Reamer *TL3-A011-xx* can also be used to remove disc material and cartilaginous tissue, and prepare the endplates.

Apply the **reamer** parallel to the intervertebral space and carefully do a quarter turn clockwise.

It is recommended to preserve as much of the annulus as possible to provide additional support for the Hexanium PLIF implant.





Straight Rake Curette
TL3-A033

Ring Curette (Left or Right)
TL3-A035-L/R

If needed, the **straight rake curette** *TL3-A033* is available to complete the endplate preparation. Insert the curette parallel to endplate and use it to remove disc space material.

In order to remove the tissue in the far lateral disc space, use the **ring curette** (left or right) *TL3-A035-L/R.*





Following the disc space material removal, it's recommended to perform a new distraction with the last used **spreader** *TL3-A010-xx.*



Straight Convex Rasp
TL3-A037-01



Curved Convex Rasp
TL3-A037-02

After completing the discectomy, use the **straight convex** or the **curved convex rasp** *TL3-A037-01* & *TL3-A037-02* to remove superficial cartilaginous tissue of the endplates.

Rasps are used to reveal the bleeding bone and ensure good vascularization of the bone graft.

Removing too much subchondral bone may weaken the vertebral endplate. A subsidence and a loss of segmental stability may happen if the entire endplate is removed.



IV IMPLANT'S SIZE ESTIMATION



Ti PLIF Trials Rack X° (PL2-RACK5, PL2-RACK8)
Ti PLIF Cage Trial (Small) PL2-A013-Sxxx
Ti PLIF Cage Trial (Medium) PL2-A013-Mxxx



Ti TLIF Cage & Trial Holder
TL3-A012

Cage Holder Handle
TL3-A002

Ti PLIF cage trials *PL2-A013-Sxx* & *PL2-A013-Mxx* are available to match the height, lordosis and footprint of each implant. Trials are separated in the **Ti PLIF trials rack** *PL2-RACKX* according to their footprint (« S » for Small footprint and « M » for Medium footprint).

To attach the **Ti PLIF cage trials** *PL2-A013-Sxx* & *PL2-A013-Mxx* to the **Ti TLIF Cage & Trial Holder** *TL3-A012*, place the distal part of the trial holder completely perpendicular to the trials rack so the trial holder and the cage trial are vertically aligned.

Turn the **Ti TLIF Cage & Trial Holder** *TL3-A012* knob clockwise to tighten the cage trial against the trial holder. Make sure that it is tightened enough and the connection is secure.



! WARNING !
Recheck and make sure the cage trial is firmly connected to the Ti TLIF Cage & Trial Holder, which can be checked manually by applying pressure on the lateral side of the cage trial with the thumb to make sure that the trial is strongly connected.

The proper alignment of the **trial** and the **Ti TLIF Cage & Trial Holder** *TL3-A012* ensures a straight introduction of the trial along the posterior route.

Insert the **Ti PLIF cage trial** *PL2-A013-Sxx* & *PL2-A013-Mxx* with gentle taps on the back of the **Cage holder handle** *TL3-A002* until it is inside the intervertebral space.

If necessary, the cage trial can be pushed forward into the intervertebral disc space with light hammering on the **Cage holder handle** *TL3-A002*.

Remove the **cage trial** Implant after cage size determination.



It's important to check the position and fit of the **cage trial** by using fluoroscopy. The tip should be placed near the anterior edge of the adjacent vertebral bodies.

! WARNING !
The trial device must never be disconnected from the Ti PLIF cage & trial holder during this step (from insertion & positioning to removal from intervertebral space).





V CAGE BONE GRAFT FILLING



Ti PLIF Cage (Small or Medium)
PL2-CSxx or PL2-CMxx

Ti PLIF/sTLIF Cage Graft Compactor
TL3-A024



Ti PLIF/sTLIF Cage Packing block
TL3-A023

Select the implant which corresponds to the **Ti PLIF Cage Trial** used in previous step.

Connect the **Ti PLIF Cage** to the **Ti TLIF Cage & Trial Holder** *TL3-A012* (described in previous part, page 6).

Place the implant in the correct slot on the **Ti PLIF/sTLIF Cage Packing Block** *TL3-A023* according to the type of the chosen cage: PLIF or sTLIF.

1 Add some bone graft in the **Ti PLIF cage** bone graft chambers.

2 To compact the graft into the implant, use the tip of the **Ti PLIF/sTLIF Cage Graft Compactor** *TL3-A024* which corresponds to the proper type of cage (PLIF or sTLIF).

3 Repeat this step until the desired bone graft volume have been compacted in the cage chamber.



VI CAGE INSERTION



Ti PLIF Cage (Small or Medium)
PL2-CSxx or PL2-CMxx

Ti TLIF Cage & Trial Holder
TL3-A012

Cage Holder Handle
TL3-A002

1 Insert on a side the **Ti TLIF Cage & Trial Holder** *TL3-A012* into the intervertebral space.

If necessary, apply a light hammering on the **cage holder handle** *TL3-A002* while maintaining the intervertebral disc height by using the appropriate **spreaders** *TL3-A010-xx* on the opposite side.

It is recommended to use fluoroscopy to confirm position of the cage.

The tip should be positioned near the anterior edge of the adjacent vertebral bodies.

2 Disconnect the **Ti TLIF Cage & Trial Holder** *TL3-A012* from the first implant. Remove the **spreader** on the opposite side by making a 90° rotation.

3 Insert the second **Ti PLIF Cage** as described for the first and then disconnect the **Ti TLIF Cage & Trial Holder.**

! WARNING !
Recheck and make sure the cage holder is firmly connected to the Ti PLIF Cage, which can be checked manually by applying pressure on the lateral side of the cage with the thumb to make sure that the cage is strongly connected.





VII CAGE REPOSITIONING

Ti Straight TLIF Cage Repositioner
TL3-A026



Ti PLIF Cage (Small or Medium)
PL2-CSxx or PL2-CMxx

OPTIONAL

To reposition the cage, use the **Ti Straight TLIF Cage Repositioner** *TL3-A026*.

Insert it into the intervertebral space, putting it in contact with the posterior end of the cage and use it to push the cage into a more anterior and/or lateral position.

Use fluoroscopy to confirm final position of the cage.



VIII CAGE REMOVAL



Sliding Hammer
TL3-A025

Ti TLIF Cage & Trial Holder
TL3-A012

Cage Holder Handle
TL3-A002

1 Connect the **Ti TLIF Cage & Trial Holder** *TL3-A012* to the implanted cage. Approach the threated extension of the Ti TLIF Cage & Trial Holder.

2 When the cage holder meets the cage, turn the knob clockwise to tighten the Cage with the cage holder.



Remove the **Ti PLIF cage** using the slot of the **sliding hammer** *TL3-A025*.

Connect the **sliding hammer** on the **cage holder handle** *TL3-A002* cap.

1 Bind the two together by doing one quarter turn with the hammer until the laser mark on the **sliding hammer** meets the mark on the **cage holder handle** cap.

2 While holding the **cage holder handle** with one hand, apply an upward force to the **sliding hammer** with the other hand.

Repeat this procedure until the cage is completely removed from the intervertebral disc space.



1 INSTRUMENTS

	Dura Retractor 06 mm	PL1-A001-06
	Dura Retractor 08 mm	PL1-A001-08
	Spreader (7 To 16)	TL3-A010-XX
	**Reamer (7 To 16)**	TL3-A011-XX
	**Snap-On Cannulated Silicon T-Handle**	SD-ATSH1169214C5
	**Straight Rake Curette**	TL3-A033

	**Ring Curette Left**	TL3-A035-L
	Ring Curette Right	TL3-A035-R
	Straight Convex Rasp	TL3-A037-01
	**Curved Convex Rasp**	TL3-A037-02
	Cage Holder Handle	TL3-A002
	**Ti TLIF Cage & Trial Holder**	TL3-A012
	Sliding Hammer	TL3-A025

	**Ti PLIF/sTLIF Cage Packing block**	TL3-A023
	Ti PLIF/sTLIF Cage Graft Compactor	TL3-A024
	Ti Straight TLIF Cage Repositioner	TL3-A026
	Ti PLIF Cage Trial (Small 7 To 16)	PL2-A013-Sxxx
	**Ti PLIF Cage Trial (Medium 7 To 16)**	PL2-A013-Mxxx
	**Ti PLIF Trials Rack**	PL2-RACKX
	**Curettes Tray**	TL3-TRAY111

	**Spreaders Tray**	TL3-TRAY112
	**Ti PLIF/sTLIF Instruments Tray**	PL2-TRAY111
	**SV Base commune DIN 1/1 H68 mm**	SD-BASE1168
	**SV Base commune DIN 1/1 H117 mm**	SD-BASE11117
	SV couvercle commun DIN 1/1	SD-LID11

Lordosis: 5°





Ti PLIF Cage Small Length 22 mm Width 9 mm	Height	Ti PLIF Cage Medium Length 25 mm Width 9 mm
PL2-CS075	07 mm	PL2-CM075
PL2-CS085	08 mm	PL2-CM085
PL2-CS095	09 mm	PL2-CM095
PL2-CS105	10 mm	PL2-CM105
PL2-CS115	11 mm	PL2-CM115
PL2-CS125	12 mm	PL2-CM125
PL2-CS135	13 mm	PL2-CM135
PL2-CS145	14 mm	PL2-CM145
PL2-CS155	15 mm	PL2-CM155
PL2-CS165	16 mm	PL2-CM165

Lordosis: 8°





Ti PLIF Cage Small Length 22 mm Width 9 mm	Height	Ti PLIF Cage Medium Length 25 mm Width 9 mm
PL2-CS078	07 mm	PL2-CM078
PL2-CS088	08 mm	PL2-CM088
PL2-CS098	09 mm	PL2-CM098
PL2-CS108	10 mm	PL2-CM108
PL2-CS118	11 mm	PL2-CM118
PL2-CS128	12 mm	PL2-CM128
PL2-CS138	13 mm	PL2-CM138
PL2-CS148	14 mm	PL2-CM148
PL2-CS158	15 mm	PL2-CM158
PL2-CS168	16 mm	PL2-CM168

SPINEVISION

INNOVATION THAT MATTERS

Distributed by

SPINEVISION
10 Rue de la Renaissance
92160 ANTONY - FRANCE
Tél : +33 1 53 33 25 25

www.spinevision.net

See package insert
for labeling limitation

Non contractual
document GPL2-ST_02US